 |
|
|
| |
Safety and Pharmacokinetics of Oral
Islatravir Once Monthly for HIV
Pre-exposure Prophylaxis (PrEP):
Week 24 Analysis of a Phase 2a Trial
|
| |
| |
IAS 2021 July 18-22
Sharon Hillier1, Linda-Gail Bekker2, Sharon A. Riddler3, Craig W. Hendrix4, Sharlaa Badal-Faesen5, Scott Rasmussen6, Howard Schwartz7, Pippa Macdonald2, Johannes Lombaard8, Yoseph Caraco9, Avivit Peer10, Munjal Patel11, Barbara Evans11, Brenda Homony11, Katherine Nedrow11, Valerie Teal11, Peggy Hwang11, Michael N. Robertson11, Rebeca M. Plank11
1Magee-Womens Research Institute & Foundation, Pittsburgh, PA, 2Desmond Tutu HIV Centre, Cape Town, South Africa, 3University of Pittsburgh, Pittsburgh, PA, 4John Hopkins Hospital, Baltimore, MD, 5Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa, 6Celerion, Lincoln, NE, 7Research Centers of America, Hollywood, FL, 8Josha Research, Bloemfontein, South Africa, 9Hadassah Medical Center, Jerusalem, Israel, 10Rambam Health Care Campus, Haifa, Israel, 11Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
